Multicenter Study Demonstrates 29% Reduction in Vasoactive Infusion Time with Use of Etiometry’s AI Powered Clinical Intelligence Platform

Study published in Critical Care Medicine highlights impact of IDO2-informed decision support on reducing postoperative support duration

June 17, 2025 – BOSTON – A newly published multicenter clinical trial in Critical Care Medicine shows that use of Etiometry’s Clinical Intelligence Platform—specifically its Inadequate Delivery of Oxygen (IDO2) Index—was associated with a significant reduction in the duration of vasoactive and inotropic infusions following pediatric cardiac surgery, potentially lowering the side effects associated with long term use of these medications.

The study, Risk Analytics Clinical Decision Support Decreases Duration of Vasoactive Infusions Following Pediatric Cardiac Surgery: A Multicenter Before and After Clinical Trial, evaluated how implementation of Etiometry’s risk analytics influenced postoperative care in pediatric cardiac ICUs. Across five institutions, 343 patients were enrolled in the intervention group using Etiometry’s platform, while 432 served as historical controls. Using a risk-adjusted negative binomial regression model, the study found a 29% reduction in vasoactive infusion duration in the intervention group compared to controls (95% CI: 14–42%, p < 0.01).

“This study marks a defining shift in pediatric cardiac critical care,” said lead author Dr. Avihu Gazit, who did the research while at Washington University in St. Louis and is now Chief of Pediatric Cardiac Critical Care Medicine at the University of Pittsburgh. “By integrating real-time physiologic analytics through IDO2, we were able to guide de-escalation of care in a way that supports clinical decisions during the recovery phase, when patients are stabilizing. Our findings highlight how predictive analytics can meaningfully influence bedside decision- making and potentially extend to other areas like sedation and mechanical ventilation.”

The IDO2 Index, a proprietary component of Etiometry’s platform, uses real-time physiologic and laboratory data to assess the likelihood of insufficient oxygen delivery. Clinicians in the study used the IDO2 trend to support decisions around titration and weaning of inotropic and vasoactive therapies in the early postoperative period.

This study adds to the growing body of evidence. Studies where Etiometry supported clinician workflows have shown associations with improvements in pediatric cardiac outcomes, including reductions in mechanical ventilation, ICU length of stay, and now, vasoactive support duration.

To access the full study, visit:
https://journals.lww.com/ccmjournal/abstract/9900/risk_analytics_clinical_decision_support_decreases.520.aspx

###

About Etiometry

Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in intensive care units make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times. Etiometry has received 10 FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization.

To learn more, visit www.etiometry.com.

These results are observational; the Etiometry Platform is intended to aid decision-making, not to
improve outcomes independently.

Media Contact
Hyedi Nelson
Bellmont Partners
Hyedi@bellmontpartners.com